MENU
ACLX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Arcellx (ACLX) Ownership - Who owns Arcellx?
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases... Show more
Profile
Industry
N/A
Address
800 Bridge Parkway
Phone
+1 240 327-0603
Employees
130
Web
https://www.arcellx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
3.91B
P/E Ratio
N/A
Total Cash
543.27M
Projected Growth
N/A
Total Debt
53.19M
Revenue
76.81M
Risk (Beta)
0.63
Dividend Yield
N/A
Total Cash/Share
9.80
Total Debt/Equity
N/A
Revenue/Share
1.04 USD as % of share price
Fundamentals
ACLX
Capitalization
3.91B
P/E Ratio
N/A
Risk (Beta)
0.63
Dividend Yield
N/A
Total Cash
543M
Total Cash/Share
9.80
Total Debt
53.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.04%
Revenue
76.8M
ROE
N/A
Book Value
417M
P/B Ratio
9.97
Cash Flow
N/A
Earnings
-2.99
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
54K
Current Ratio
4.93
Current Revenue Per Employee
49871.16
Dividends Per Share - Security
N/A
EBITDA
-153.96M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-22.75
Shares Held By Institutions
5.71B
Shares Outstanding - Current
55.5M
Total Liabilities
231M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-8.071
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACLX showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
800 Bridge Parkway
Phone
+1 240 327-0603
Employees
130
Web
https://www.arcellx.com